Pharma CDx Growth Foundation Medicine is actively expanding its companion diagnostics footprint through long-running collaborations with major pharma (for example with Bristol Myers Squibb) to develop FoundationOne CDx and MTAP biomarker tests across multiple indications. This signals a strong sales arc for new CDx development, regulatory support, and test modernization, presenting opportunities to propose end-to-end CDx programs, regulatory-grade data packages, and integrated lab services to sponsors.

Global Expansion The acquisition of Saga Diagnostics AB and Roche affiliation position FMI to scale internationally, enabling access to European markets and expanded biomarker capabilities. For sales, target multinational pharma and CROs with cross-border diagnostic solutions, clinical trial support, and harmonized testing workflows across regions.

Data and AI Advantage FMI leverages real-world data and AI-powered tools to accelerate therapy development and improve patient outcomes, and partners with ConcertAI to combine data assets. This creates a differentiated offering for life sciences sponsors seeking RWE, post-market surveillance, and evidence-based labeling; propose data-sharing arrangements, RWE pipelines, and regulatory-grade analytics services.

Core Test Platform FoundationOne CDx is central to FMIs strategy as a broad NGS-based companion diagnostic in oncology across indications, underscoring demand for comprehensive molecular profiling. Sales opportunities include approaching sponsors with CDx-backed trial design, upfront biomarker strategy, scalable lab partnerships, and integration with LIMS and electronic health record workflows.

Science Leadership FMI demonstrates leadership in cancer biomarker testing and clinical trial presentations, including ASCO, signaling credibility and collaboration opportunities. Propose co-marketing, scientific advisory collaborations, and sponsored research programs with pharma and academic partners to accelerate trial recruitment and biomarker validation.